An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation.

Key Inclusion Criteria (Module 1) - Subjects must be at least 18 years of age - Subject must be diagnosed with one of the histologies below: - NSCLC - Colorectal adenocarcinoma - HNSCC - Pancreatic adenocarcinoma - Breast cancer - Ovarian cancer - Any other solid tumor - Tumors must harbor a TP53 R175H variant mutation and subject must be HLA-A*02:01 positive (at least 1 allele) - Subject has advanced solid cancer, defined as unresectable, advanced, and/or metastatic disease (Stage III or IV) after at least 1 line of approved systemic standard of care (SOC) treatment regimen and for which there are no available curative treatment options. - Subject has at least 1 measurable lesion - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 - Adequate hematological, renal, hepatic, pulmonary, and cardiac function Key Exclusion Criteria (Module 1) - Any another primary malignancy within the 3 years prior to enrollment - Known, active primary central nervous system (CNS) malignancy - History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation. - History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment. - Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter, prior to enrollment. - Any form of primary immunodeficiency. - Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome. Key Inclusion Criteria (Module 2 - hematological malignancies) - At least 18 years of age - Diagnosis of AML or MDS that allows for efficacy assessments - Confirmation of TP53 R175H variant mutation in cancer cells - Subject must be HLA-A*02:01 positive (at least 1 allele) - ECOG performance status of 0 to 1 Key Exclusion Criteria (Module 2 - hematological malignancy) - Acute promyelocytic leukaemia or isolated extramedullary disease - Another primary malignancy within 2 years (with exceptions) - HSCT within 100 days or immunosuppression for GvHD within 4 weeks - History of CNS or other extramedullary leukaemic involvement unless a lumbar puncture is negative for leukemic cells - Prior stroke, ischemic attack, significant cardiac disease, heart failure - Prior adoptive modified cell therapy - Known to have Li-Fraumeni syndrome or is known to have relatives who are diagnosed with Li-Fraumeni syndrome.